Johnson & Johnson and Bayer are wont to brag about their achievements with Xarelto, one of the new generation of anticoagulant meds. Rightfully so: Though second to that market by many months, the companies grabbed market share from their old standby rival warfarin and their head-to-head competition Pradaxa, too.
Australia's Sirtex may be on the radar of Bayer AG as the two companies focus on radiation treatments for liver cancers and see Singapore as a key regional location for clinical and sales efforts in regional oncology.
When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.
Bayer HealthCare's whistle-blowing sales rep finally got a job offer at his old company. Thing is, that offer was 500 miles away from home--and a U.S. judge was none too impressed with the gambit.
Debiotech has gained an option with Oregon-based iSense CGM to acquire exclusive rights to use its continuous glucose monitoring technology with patch insulin pumps for diabetes treatment. The companies expect that the integration of Debiotech's Jewel Pump with the iSense continuous glucose monitor technology could lead to the creation of an accurate artificial pancreas--a device that continuously measures insulin levels and then automatically dispenses insulin accordingly in response.
Bayer responded to an article in The New York Times critical of the company's Essure contraceptive inserts with a letter to the editor that claims the story "mischaracterizes" a recently published long-term study of the device.
Doubling down on its in-house startup academy, biotech VC stalwart Flagship Ventures has recruited a trio of big-name corporate sponsors to lend their expertise to its next class of seedlings, expanding its focus well beyond traditional drug development.
Bayer Healthcare is stepping up with $155 million in cash and a big near-term milestone in exchange for the development and commercialization rights to an experimental anticoagulant from Isis Pharmaceuticals.
Under investigation by the FDA following claims of dangerous side effects and fraudulent clinical trial data, Bayer has released new data from a long-term study the German drugmaker says supports the safety and effectiveness of its Essure contraceptive inserts.
The average upfront value in biotech deals hit a 9-year peak in 2014, according to Morrison & Foerster, part of a virtuous cycle in life sciences that has pushed asset valuations ever upward.